This is particularly relevant to drug discovery for Chagas disease where a considerable proportion of hits identified through phenotypic screening have been found to target CYP51 (15), a discredited target following the failure of posaconazole in clinical trials (11). The gene discussed is CYP51A1; the disease is Chagas disease.